PL3793586T3 - Warianty rozpuszczalnego receptora układu dopełniacza typu 1 i ich zastosowania - Google Patents
Warianty rozpuszczalnego receptora układu dopełniacza typu 1 i ich zastosowaniaInfo
- Publication number
- PL3793586T3 PL3793586T3 PL19803150.2T PL19803150T PL3793586T3 PL 3793586 T3 PL3793586 T3 PL 3793586T3 PL 19803150 T PL19803150 T PL 19803150T PL 3793586 T3 PL3793586 T3 PL 3793586T3
- Authority
- PL
- Poland
- Prior art keywords
- variants
- receptor type
- complement receptor
- soluble complement
- soluble
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018901703A AU2018901703A0 (en) | 2018-05-16 | Soluble complement receptor Type I variants and uses thereof | |
| PCT/AU2019/050456 WO2019218009A1 (en) | 2018-05-16 | 2019-05-15 | Soluble complement receptor type 1 variants and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3793586T3 true PL3793586T3 (pl) | 2024-08-05 |
Family
ID=68539129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19803150.2T PL3793586T3 (pl) | 2018-05-16 | 2019-05-15 | Warianty rozpuszczalnego receptora układu dopełniacza typu 1 i ich zastosowania |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20210238238A1 (pl) |
| EP (2) | EP3793586B1 (pl) |
| JP (2) | JP2021524846A (pl) |
| KR (1) | KR102854142B1 (pl) |
| CN (1) | CN112118859A (pl) |
| AU (1) | AU2019268410B2 (pl) |
| BR (1) | BR112020022405A2 (pl) |
| CA (1) | CA3100071A1 (pl) |
| DK (1) | DK3793586T3 (pl) |
| ES (1) | ES2991497T3 (pl) |
| FI (1) | FI3793586T3 (pl) |
| HR (1) | HRP20240684T1 (pl) |
| HU (1) | HUE067014T2 (pl) |
| PL (1) | PL3793586T3 (pl) |
| PT (1) | PT3793586T (pl) |
| SG (1) | SG11202010596PA (pl) |
| SI (1) | SI3793586T1 (pl) |
| WO (1) | WO2019218009A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX349035B (es) * | 2012-05-17 | 2017-07-07 | Extend Biosciences Inc | Portadores para el suministro mejorado de farmaco. |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| CN113637084B (zh) * | 2020-05-11 | 2025-08-01 | 上海康景生物医药科技有限公司 | 生物大分子靶向特异性补体抑制剂及其制备方法与应用 |
| WO2021257480A2 (en) | 2020-06-14 | 2021-12-23 | Catalyst Biosciences, Inc. | Complement factor i-related compositions and methods |
| CN112898437B (zh) * | 2021-03-24 | 2024-02-02 | 思格(苏州)生物科技有限公司 | 一种新冠病毒抗原及其制备方法与应用 |
| CN116162149A (zh) * | 2022-12-06 | 2023-05-26 | 苏州绶草生物科技有限公司 | 一种提高植物中合成重组人血清白蛋白基因表达量的方法 |
| CN116004645B (zh) * | 2023-01-13 | 2025-07-08 | 新乡医学院 | 一种利用昆虫细胞生产人血清白蛋白的方法、核苷酸序列及表达载体 |
| CN122055380A (zh) * | 2023-09-15 | 2026-05-15 | 杰特创新私人有限公司 | 可溶性补体受体1型变体及其用途 |
| EP4559472A1 (en) * | 2023-11-24 | 2025-05-28 | Universität Ulm | Complement modulator |
| AU2024384696A1 (en) * | 2023-11-24 | 2026-06-04 | Universität Ulm | Complement modulator |
| WO2025184419A1 (en) * | 2024-02-29 | 2025-09-04 | Kodiak Sciences Inc. | Engineered complement inhibitor proteins |
| CN121378515B (zh) * | 2025-12-23 | 2026-04-07 | 鄂尔多斯市中心医院(内蒙古自治区超声影像研究所) | 一种抗凝血融合蛋白HSA-Qinghaienin(c)和编码基因及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981481A (en) * | 1974-12-06 | 1999-11-09 | The Johns Hopkins University | Human C3b/C4b receptor (CR1) |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5256642A (en) * | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| AU1674292A (en) | 1991-03-15 | 1992-10-21 | Synergen, Inc. | Pegylation of polypeptides |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| DE69328098T2 (de) | 1992-06-24 | 2000-08-24 | Adprotech Plc, Royston | Lösliche derivate des complement type-rezeptors (cr1) |
| US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| CA2145278C (en) | 1992-09-25 | 2009-03-10 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
| CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| DK0730608T3 (da) | 1993-05-17 | 2002-07-22 | Avant Immunotherapeutics Inc | Præparater omfattende komplementrelaterede proteiner og carbohydrater og fremgangsmåder til fremstilling og anvendelse af præparaterne |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| DE69942334D1 (de) | 1998-03-02 | 2010-06-17 | Massachusetts Inst Technology | Poly-zinkfinger-proteine mit verbesserten linkern |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| ATE480562T1 (de) | 2002-10-15 | 2010-09-15 | Facet Biotech Corp | Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese |
| AU2004245038A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-CD3 antibody |
| AU2004271200A1 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2007019620A1 (en) | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
| CN101341254A (zh) * | 2005-12-24 | 2009-01-07 | 蒂加斯克乳制品研究中心 | 反-10,顺-12十八碳二烯酸的生产方法 |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| AU2010311332B2 (en) | 2009-10-30 | 2015-04-23 | Albumedix Ltd. | Albumin variants |
| WO2011103076A1 (en) | 2010-02-16 | 2011-08-25 | Medlmmune, Llc | Hsa-related compositions and methods of use |
| MX2012013233A (es) * | 2010-05-14 | 2013-05-20 | Univ Colorado Regents | Grupos que apuntan a receptor 2 de complemento (cr2) mejorados. |
| JP2013533217A (ja) * | 2010-05-17 | 2013-08-22 | セビックス・インコーポレイテッド | Peg化c−ペプチド |
| JP6092776B2 (ja) * | 2010-09-15 | 2017-03-08 | セルデックス セラピューティクス インコーポレイテッド | 可溶性補体受容体I型(sCR1)を用いる慢性腎症の処置 |
| AU2011319746B2 (en) * | 2010-10-27 | 2015-07-30 | Celldex Therapeutics, Inc. | Method of improving transplant function using soluble complement receptor type I (sCR1) |
| EP2675471A4 (en) | 2011-02-15 | 2015-01-28 | Medimmune Llc | HSA-RELATED COMPOSITIONS AND USE PROCESSES |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| BR112014013205A2 (pt) * | 2011-12-01 | 2020-10-27 | Protevobio, Inc. | proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit |
| CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
| WO2014179657A1 (en) | 2013-05-03 | 2014-11-06 | Eleven Biotherapeutics, Inc. | Albumin variants binding to fcrn |
| EP3063171B1 (en) | 2013-11-01 | 2019-07-24 | University Of Oslo | Albumin variants and uses thereof |
| CN106456744A (zh) * | 2014-04-01 | 2017-02-22 | 鲁比厄斯治疗法股份有限公司 | 用于免疫调节的方法和组合物 |
| KR102715492B1 (ko) | 2017-10-18 | 2024-10-11 | 씨에스엘 리미티드 | 인간 혈청 알부민 변이체 및 이의 용도 |
-
2019
- 2019-05-15 CN CN201980032779.6A patent/CN112118859A/zh active Pending
- 2019-05-15 BR BR112020022405-7A patent/BR112020022405A2/pt unknown
- 2019-05-15 CA CA3100071A patent/CA3100071A1/en active Pending
- 2019-05-15 FI FIEP19803150.2T patent/FI3793586T3/fi active
- 2019-05-15 SG SG11202010596PA patent/SG11202010596PA/en unknown
- 2019-05-15 EP EP19803150.2A patent/EP3793586B1/en active Active
- 2019-05-15 ES ES19803150T patent/ES2991497T3/es active Active
- 2019-05-15 JP JP2020564231A patent/JP2021524846A/ja active Pending
- 2019-05-15 HU HUE19803150A patent/HUE067014T2/hu unknown
- 2019-05-15 US US17/053,981 patent/US20210238238A1/en active Pending
- 2019-05-15 HR HRP20240684TT patent/HRP20240684T1/hr unknown
- 2019-05-15 AU AU2019268410A patent/AU2019268410B2/en active Active
- 2019-05-15 WO PCT/AU2019/050456 patent/WO2019218009A1/en not_active Ceased
- 2019-05-15 DK DK19803150.2T patent/DK3793586T3/da active
- 2019-05-15 PL PL19803150.2T patent/PL3793586T3/pl unknown
- 2019-05-15 SI SI201930761T patent/SI3793586T1/sl unknown
- 2019-05-15 EP EP24159300.3A patent/EP4410379A3/en active Pending
- 2019-05-15 PT PT198031502T patent/PT3793586T/pt unknown
- 2019-05-15 KR KR1020207036132A patent/KR102854142B1/ko active Active
-
2024
- 2024-04-12 JP JP2024064677A patent/JP2024096868A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4410379A2 (en) | 2024-08-07 |
| CA3100071A1 (en) | 2019-11-21 |
| SI3793586T1 (sl) | 2024-07-31 |
| EP4410379A3 (en) | 2024-10-02 |
| EP3793586A1 (en) | 2021-03-24 |
| SG11202010596PA (en) | 2020-11-27 |
| KR102854142B1 (ko) | 2025-09-04 |
| AU2019268410A1 (en) | 2020-12-17 |
| US20210238238A1 (en) | 2021-08-05 |
| JP2021524846A (ja) | 2021-09-16 |
| HUE067014T2 (hu) | 2024-09-28 |
| EP3793586A4 (en) | 2022-04-06 |
| PT3793586T (pt) | 2024-07-10 |
| DK3793586T3 (da) | 2024-06-10 |
| AU2019268410B2 (en) | 2025-01-02 |
| EP3793586B1 (en) | 2024-04-10 |
| BR112020022405A2 (pt) | 2021-04-13 |
| CN112118859A (zh) | 2020-12-22 |
| FI3793586T3 (fi) | 2024-07-10 |
| KR20210013091A (ko) | 2021-02-03 |
| WO2019218009A1 (en) | 2019-11-21 |
| ES2991497T3 (es) | 2024-12-03 |
| JP2024096868A (ja) | 2024-07-17 |
| HRP20240684T1 (hr) | 2024-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202010596PA (en) | Soluble complement receptor type 1 variants and uses thereof | |
| AU2018901703A0 (en) | Soluble complement receptor Type I variants and uses thereof | |
| GB201819753D0 (en) | Concept 201 | |
| GB201817929D0 (en) | Concept 192 | |
| GB201814415D0 (en) | Concept 36 | |
| GB201814406D0 (en) | Concept 30 | |
| GB201813656D0 (en) | Concept 179 | |
| GB201810890D0 (en) | Concept 175 | |
| GB201809927D0 (en) | Concept 178 | |
| GB201809434D0 (en) | Concept 174 | |
| GB201808988D0 (en) | Concept 171 | |
| GB201808985D0 (en) | Concept 173 | |
| GB201808987D0 (en) | Concept 172 | |
| GB201807532D0 (en) | Concept 170 | |
| GB201807127D0 (en) | Concept 39 | |
| GB201807128D0 (en) | Concept 38 | |
| GB201807078D0 (en) | Concept 169 | |
| GB201807131D0 (en) | Concept 43 | |
| GB201807093D0 (en) | Concept 21 | |
| GB201807097D0 (en) | Concept 11 | |
| GB201807117D0 (en) | Concept 32 | |
| GB201807084D0 (en) | Concept 33 | |
| GB201807083D0 (en) | Concept 29 | |
| GB201807121D0 (en) | Concept 33 | |
| GB201807079D0 (en) | Concept 168 |